Varenicline Is a Partial Agonist at α4β2 and a Full Agonist at α7 Neuronal Nicotinic Receptors

Cited by (583)

Items 101–200 of 583

1. Nicotine addiction and psychiatric disorders
   Kutlu, Munir Gunes, Parikh, Vinay, Gould, Thomas J. · 2015 · International Review of Neurobiology
2. Rodent models for nicotine withdrawal
   Ranjithkumar Chellian, Azin Behnood‐Rod, Dawn M. Bruijnzeel, Ryann Wilson, Vijayapandi Pandy, Adriaan W. Bruijnzeel · 2021 · Journal of Psychopharmacology
3. Neurocognitive endophenotypes in schizophrenia: Modulation by nicotinic receptor systems
   Kristen M. Mackowick, Mera S. Barr, Victoria C. Wing, Rachel Allison Rabin, Clairélaine Ouellet‐Plamondon, Tony Peter George · 2013 · Progress in Neuro-Psychopharmacology and Biological Psychiatry
4. Activation and Inhibition of Mouse Muscle and Neuronal Nicotinic Acetylcholine Receptors Expressed in Xenopus Oocytes
   Roger L. Papke, Lynn Wecker, Jerry A. Stitzel · 2010 · Journal of Pharmacology and Experimental Therapeutics
5. The nicotinic acetylcholine receptor partial agonist varenicline and the treatment of drug dependence: A review
   Cleo Lina Crunelle, Michelle L. Miller, Jan Booij, Wim van den Brink · 2009 · European Neuropsychopharmacology
6. Cognitive Deficits in Schizophrenia: Focus on Neuronal Nicotinic Acetylcholine Receptors and Smoking
   Enrique L. M. Ochoa, Jose Antonio Lasalde‐Dominicci · 2007 · Cellular and Molecular Neurobiology
7. Nicotinic cholinergic system and COVID-19: In silico evaluation of nicotinic acetylcholine receptor agonists as potential therapeutic interventions
   Nikolaos Alexandris, George Lagoumintzis, Christos T. Chasapis, Demetres D. Leonidas, Georgios E. Papadopoulos, Socrates J. Tzartos, Aristidis Michael Tsatsakis, Elias Eliopoulos, Konstantinos A. Poulas, Konstantinos E. Farsalinos · 2020 · Toxicology Reports
8. Varenicline ameliorates nicotine withdrawal-induced learning deficits in C57BL/6 mice.
   Raybuck, Jonathan D., Portugal, George S., Lerman, Caryn, Gould, Thomas J. · 2008 · Behavioral Neuroscience
9. Role for the nicotinic cholinergic system in movement disorders; therapeutic implications
   Maryka Quik, Danhui Zhang, Xiomara A. Perez, Tanuja Bordia · 2014 · Pharmacology & Therapeutics
10. Determining the pharmacokinetics of nicotinic drugs in the endoplasmic reticulum using biosensors
    Amol V. Shivange, Philip M. Borden, Anand K. Muthusamy, Aaron L. Nichols, Kallol Bera, Huan Bao, Isaac Bishara, Janice Jeon, Matthew J. Mulcahy, Bruce N. Cohen et al. · 2019 · The Journal of General Physiology
11. Nicotine reduces established levodopa‐induced dyskinesias in a monkey model of Parkinson's disease
    Maryka Quik, Archana Mallela, Jason Ly, Danhui Zhang · 2013 · Movement Disorders
12. Results from a pilot clinical trial of varenicline for the treatment of alcohol dependence
    Jennifer G. Plebani, Kevin G. Lynch, Lior Rennert, Helen M. Pettinati, Charles P. O’Brien, Kyle Matthew Kampman · 2013 · Drug and Alcohol Dependence
13. Nicotinic Receptor Contributions to Smoking: Insights from Human Studies and Animal Models
    Darlene H. Brunzell, Alexandra M. Stafford, Claire I. Dixon · 2015 · Current Addiction Reports
14. MiR-153 targets the nuclear factor-1 family and protects against teratogenic effects of ethanol exposure in fetal neural stem cells
    Pai-Chi Tsai, Shameena Bake, Sridevi Balaraman, Jeremy A. Rawlings, Rhonda Holgate, Dustin W. DuBois, Rajesh C. Miranda · 2014 · Biology Open
15. Moderators of Varenicline Treatment Effects in a Double-Blind, Placebo-Controlled Trial for Alcohol Dependence
    Daniel E. Falk, I‐Jen P. Castle, Megan Ryan, Joanne B. Fertig, Raye Z. Litten · 2015 · Journal of Addiction Medicine
16. Varenicline attenuates nicotine-enhanced brain-stimulation reward by activation of α4β2 nicotinic receptors in rats
    Spiller, Krista, Xi, Zheng-Xiong, Li, Xia, Ashby, Charles R., Callahan, Patrick M., Tehim, Ashok, Gardner, Eliot L. · 2009 · Neuropharmacology
17. ONSET-1 Phase 2b Randomized Trial to Evaluate the Safety and Efficacy of OC-01 (Varenicline Solution) Nasal Spray on Signs and Symptoms of Dry Eye Disease
    David Wirta, Gail L. Torkildsen, Blair E. Boehmer, David Hollander, Edward Bendert, Lijuan Zeng, Michael Ackermann, Jeffrey A. Nau · 2021 · Cornea
18. Varenicline for Smoking Cessation in Schizophrenia: Safety and Effectiveness in a 12-Week Open-Label Trial
    Gladys N. Pachas, Corinne Cather, Sarah I. Pratt, Bettina B. Hoeppner, Johanna Nino, Sara V. Carlini, Eric D. Achtyes, Harry Alan Lando, Kim T. Mueser, Nancy A. Rigotti et al. · 2012 · Journal of Dual Diagnosis
19. Functional Interactions of Fibrillar and Oligomeric Amyloid-β with Alpha7 Nicotinic Receptors in Alzheimer's Disease
    Lilja, Anna M., Porras, Omar, Storelli, Elisa, Nordberg, Agneta, Marutle, Amelia · 2011 · Journal of Alzheimer's Disease
20. Nicotinic receptor modulation to treat alcohol and drug dependence
    Shafiqur Rahman, Eric A. Engleman, Richard L. Bell · 2015 · Frontiers in Neuroscience
21. Novel Pharmacological Approaches for Treating Tobacco Dependence and Withdrawal
    August R. Buchhalter, Reginald V. Fant, Jack E. Henningfield · 2008 · Drugs
22. Nicotinic receptor ligands reduce ethanol intake by high alcohol–drinking HAD-2 rats
    Richard L. Bell, Bill J.A. Eiler, Jason B. Cook, Shafiqur Rahman · 2009 · Alcohol
23. Nicotinic receptor-based therapeutics and candidates for smoking cessation
    Linda P. Dwoskin, Andrew M. Smith, Thomas E. Wooters, Zhenfa Zhang, Peter Anthony Crooks, Michael Thomas Bardo · 2009 · Biochemical Pharmacology
24. Recent Developments in Novel Antidepressants Targeting α4β2-Nicotinic Acetylcholine Receptors
    Li-Fang Yu, Han-Kun Zhang, Barbara J. Caldarone, Jason Brek Eaton, Ronald J. Lukas, Alan P. Kozikowski · 2014 · Journal of Medicinal Chemistry
25. PET imaging of α7 nicotinic acetylcholine receptors: a comparative study of [18F]ASEM and [18F]DBT-10 in nonhuman primates, and further evaluation of [18F]ASEM in humans
    Ansel T. Hillmer, Songye Li, Ming‐Qiang Zheng, Matthias Scheunemann, Shu-fei Lin, Nabeel Nabulsi, Daniel Holden, Richard Pracitto, David C. Labaree, Jim R. Ropchan et al. · 2017 · European Journal of Nuclear Medicine and Molecular Imaging
26. Nicotinic Receptor Antagonists as Treatments for Nicotine Abuse
    Peter Anthony Crooks, Michael Thomas Bardo, Linda P. Dwoskin · 2014 · Advances in pharmacology
27. An inhibitory brainstem input to dopamine neurons encodes nicotine aversion
    Christine Junhui Liu, Amanda J. Tose, Jeroen P. H. Verharen, Yichen Zhu, Lilly W. Tang, Johannes W. de Jong, Jessica X. Du, Kevin T. Beier, Stephan Lammel · 2022 · Neuron
28. Varenicline blocks nicotine intake in rats with extended access to nicotine self-administration
    Olivier George, Allison Lloyd, Frank Ivy Carroll, Mohamad Imad Damaj, George F. Koob · 2010 · Psychopharmacology
29. Neurophysiology of Nicotine Addiction
    John A. Dani, Daniel Jenson, John I. Broussard · 2012 · Journal of Addiction Research & Therapy
30. Nicotine hapten structure, antibody selectivity and effect relationships: Results from a nicotine vaccine screening procedure
    Sabina H. L. de Villiers, Nina Lindblom, Genadiy Kalayanov, Sandra Leigh Gordon, Ivan L. Baraznenok, Anna Malmerfelt, Monica M. Marcus, Anette M. Johansson, Torgny H. Svensson · 2010 · Vaccine
31. Emerging Opportunities for Antipsychotic Drug Discovery in the Postgenomic Era
    Michael J. Marino, Lars J. S. Knutsen, Michael R. Williams · 2008 · Journal of Medicinal Chemistry
32. Varenicline
    Gillian M. Keating, M Asif A Siddiqui · 2006 · CNS Drugs
33. Interoception and Learning: Import to Understanding and Treating Diseases and Psychopathologies
    Rick A. Bevins, Joyce Besheer · 2014 · ACS Chemical Neuroscience
34. Associative Learning, the Hippocampus, and Nicotine Addiction
    Thomas J. Gould, Jennifer A. Davis · 2008 · Current Drug Abuse Reviews
35. Varenicline for smoking cessation: nausea severity and variation in nicotinic receptor genes
    Gary E. Swan, Harold S. Javitz, Lisa M. Jack, Jennifer Wessel, M Michel, David A. Hinds, R P Stokowksi, Jennifer B. McClure, Sheryl L. Catz, Julie Angerhofer Richards et al. · 2011 · The Pharmacogenomics Journal
36. Multiple CNS nicotinic receptors mediate l-dopa-induced dyskinesias: Studies with parkinsonian nicotinic receptor knockout mice
    Maryka Quik, Carla Campos, Sharon R. Grady · 2013 · Biochemical Pharmacology
37. Nicotinic Receptor Agonists Reduce l-DOPA–Induced Dyskinesias in a Monkey Model of Parkinson's Disease
    Danhui Zhang, Archana Mallela, David Sohn, Frank Ivy Carroll, Merouane Bencherif, Sharon R. Letchworth, Maryka Quik · 2013 · Journal of Pharmacology and Experimental Therapeutics
38. Alcohol Interaction with Cocaine, Methamphetamine, Opioids, Nicotine, Cannabis, and γ-Hydroxybutyric Acid
    Ashok Kumar Singh · 2019 · Biomedicines
39. Nicotinic acetylcholine receptors containing α6 subunits contribute to alcohol reward‐related behaviours
    Matthew S. Powers, Hilary J. Broderick, Ryan M. Drenan, Julia A. Chester · 2013 · Genes Brain & Behavior
40. Identification of Novel α4β2-Nicotinic Acetylcholine Receptor (nAChR) Agonists Based on an Isoxazole Ether Scaffold that Demonstrate Antidepressant-like Activity
    Li-Fang Yu, Werner Tückmantel, Jason Brek Eaton, Barbara J. Caldarone, Allison Fedolak, Taleen Hanania, Dani Brunner, Ronald J. Lukas, Alan P. Kozikowski · 2011 · Journal of Medicinal Chemistry
41. Dissociation between duration of action in the forced swim test in mice and nicotinic acetylcholine receptor occupancy with sazetidine, varenicline, and 5-I-A85380
    Caldarone, Barbara J., Wang, Daguang, Paterson, Neil E., Manzano, Michael, Fedolak, Allison, Cavino, Katie, Kwan, Mei, Hanania, Taleen, Chellappan, Sheela K., Kozikowski, Alan P. et al. · 2011 · Psychopharmacology
42. Nicotine receptor partial agonists for smoking cessation
    Cahill, Kate, Stead, Lindsay F, Lancaster, Tim · 2010 · Cochrane Database of Systematic Reviews
43. Varenicline Solution Nasal Spray: A Review in Dry Eye Disease
    James E. Frampton · 2022 · Drugs
44. Varenicline for smoking cessation in people with schizophrenia: systematic review and meta-analysis
    Taro Kishi, Nakao Iwata · 2014 · European Archives of Psychiatry and Clinical Neuroscience
45. Synthesis and Structure−Activity Relationship Studies of 3,6-Diazabicyclo[3.2.0]heptanes as Novel α4β2 Nicotinic Acetylcholine Receptor Selective Agonists
    Jianguo Ji, Michael R. Schrimpf, Kevin B. Sippy, William H. Bunnelle, Tao Li, David J. Anderson, Connie R. Faltynek, Carol S. Surowy, Tino Dyhring, Philip Kiær Ahring et al. · 2007 · Journal of Medicinal Chemistry
46. Neuronal nicotinic receptor agonists improve gait and balance in olivocerebellar ataxia
    Lynn Wecker, M.E. Engberg, R.M. Philpot, Chase Steven Lambert, C.W. Kang, Jon C. Antilla, Paula C. Bickford, C.E. Hudson, Theresa A. Zesiewicz, Peter P Rowell · 2013 · Neuropharmacology
47. Cracking the Betel Nut: Cholinergic Activity of Areca Alkaloids and Related Compounds
    Nicole A. Horenstein, Marta Quadri, Clare A. Stokes, Mohammed C. Shoaib, Roger L. Papke · 2017 · Nicotine & Tobacco Research
48. The Effects of Extended Pre-Quit Varenicline Treatment on Smoking Behavior and Short-Term Abstinence: A Randomized Clinical Trial
    Larry W. Hawk, Rebecca L. Ashare, S F Lohnes, Nicolas J. Schlienz, Jessica D. Rhodes, Stephen T. Tiffany, Julie C. Gass, K. Michael Cummings, Martin Christopher Mahoney · 2011 · Clinical Pharmacology & Therapeutics
49. Lobeline and cytisine reduce voluntary ethanol drinking behavior in male C57BL/6J mice
    Ravi Kiran Sajja, Shafiqur Rahman · 2010 · Progress in Neuro-Psychopharmacology and Biological Psychiatry
50. Effects of nicotinic acetylcholine receptor agonists on cognition in rhesus monkeys with a chronic cocaine self-administration history
    Robert W. Gould, Pradeep Garg, Sudha Garg, Michael A. Nader · 2012 · Neuropharmacology
51. Cholinergic Targets in Lung Cancer
    Eliot R. Spindel · 2016 · Current Pharmaceutical Design
52. Allosteric modulators of the α4β2 subtype of Neuronal Nicotinic Acetylcholine Receptors
    Anshul A. Pandya, J. Yakel · 2011 · Biochemical Pharmacology
53. Multimodal techniques for smoking cessation: a review of their efficacy and utilisation and clinical practice guidelines
    Victor I. Reus, B. J. Smith · 2008 · International Journal of Clinical Practice
54. The Antinociceptive Effects of Nicotinic Partial Agonists Varenicline and Sazetidine-A in Murine Acute and Tonic Pain Models
    Shakir D. AlSharari, F. Ivy Carroll, J. Michael McIntosh, Mohamad Imad Damaj · 2012 · Journal of Pharmacology and Experimental Therapeutics
55. Mechanism-based medication development for the treatment of nicotine dependence
    Zheng‐Xiong Xi, Krista J. Spiller, Eliot L. Gardner · 2009 · Acta Pharmacologica Sinica
56. Diverse strategies targeting α7 homomeric and α6β2* heteromeric nicotinic acetylcholine receptors for smoking cessation
    Darlene H. Brunzell, J. Michael McIntosh, Roger L. Papke · 2014 · Annals of the New York Academy of Sciences
57. Nicotinic Mechanisms Modulate Ethanol Withdrawal and Modify Time Course and Symptoms Severity of Simultaneous Withdrawal from Alcohol and Nicotine
    Erika E. Perez, Natalia A. Quijano Cardé, Mariella De Biasi · 2015 · Neuropsychopharmacology
58. Effects of varenicline and bupropion on cognitive processes among nicotine-deprived smokers.
    Rebecca L. Ashare, Sherry A. McKee · 2011 · Experimental and Clinical Psychopharmacology
59. Varenicline for smoking cessation: a narrative review of efficacy, adverse effects, use in at-risk populations, and adherence
    Jon O. Ebbert, Michael V. Burke, James Taylor Hays · 2016 · Patient Preference and Adherence
60. New insights on the effects of varenicline on nicotine reward, withdrawal and hyperalgesia in mice
    Deniz Bağdaş, Yasmin Alkhlaif, Asti B. Jackson, Frank Ivy Carroll, Joseph W. Ditre, Mohamad Imad Damaj · 2018 · Neuropharmacology
61. High Throughput Electrophysiology with Xenopus Oocytes
    Catherine J. Smith‐Maxwell, Roger L. Papke · 2009 · Combinatorial Chemistry & High Throughput Screening
62. Neuronal Nicotinic Acetylcholine Receptor Modulators Reduce Sugar Intake
    Masroor R. Shariff, Maryka Quik, Joan Y. Holgate, Michael Morgan, Omkar L. Patkar, Vincent Tam, Arnauld Belmer, Selena E. Bartlett · 2016 · PLoS ONE
63. Unlocking Nicotinic Selectivity via Direct C‒H Functionalization of (−)-Cytisine
    Hugo Rego Campello, Silvia G. del Villar, Aurélien Honraedt, Teresa Minguez, A. Sofia F. Oliveira, Kara E. Ranaghan, Deborah K. Shoemark, Isabel Bermúdez, Cecilia Gotti, Richard Barry Sessions et al. · 2018 · Chem
64. Nicotine’ actions on energy balance: Friend or foe?
    Patricia Seoane‐Collazo, Carlos Diéguez, Rubén Nogueiras, Kamal Rahmouni, José Manuel Fernández‐Real, Miguel López · 2020 · Pharmacology & Therapeutics
65. Tobacco smoking cessation management: integrating varenicline in current practice
    Laurence M Galanti · 2008 · Vascular Health and Risk Management
66. Critical needs in drug discovery for cessation of alcohol and nicotine polysubstance abuse
    Candice E. Van Skike, Sarah E. Maggio, Anna R. Reynolds, Erin M. Casey, Michael Thomas Bardo, Linda P. Dwoskin, Mark Prendergast, Kimberly Nixon · 2015 · Progress in Neuro-Psychopharmacology and Biological Psychiatry
67. Selective α4β2 Nicotinic Acetylcholine Receptor Agonists Target Epigenetic Mechanisms in Cortical GABAergic Neurons
    Ekrem Maloku, Bashkim Kadriu, Adrian Zhubi, Erbo Dong, Fabio Pibiri, Rosalba Satta, Alessandro Guidotti · 2011 · Neuropsychopharmacology
68. Subtype-selective nicotinic acetylcholine receptor agonists enhance the responsiveness to citalopram and reboxetine in the mouse forced swim test
    Jesper Tobias Andreasen, Elsebet Østergaard Nielsen, Jeppe K. Christensen, Gunnar M. Olsen, Dan Peters, Naheed Rohman Mirza, John Paul Redrobe · 2010 · Journal of Psychopharmacology
69. Varenicline: New treatment with efficacy in smoking cessation
    Victor I. Reus, Ronald Scott Obach, Jotham W. Coe, Hélène M. Faessel, Hans Rollema, Eric J. Watsky, Karen R. Reeves · 2007 · Drugs of today
70. Effects of Varenicline on the Reinforcing and Discriminative Stimulus Effects of Cocaine in Rhesus Monkeys
    Robert W. Gould, Paul W. Czoty, Susan H. Nader, Michael A. Nader · 2011 · Journal of Pharmacology and Experimental Therapeutics
71. Effects of 21 days of varenicline versus placebo on smoking behaviors and urges among non-treatment seeking smokers
    Rebecca L. Ashare, Kathy Z. Tang, A Clementina Mesaros, Ian A. Blair, Frank T. Leone, Andrew A. Strasser · 2012 · Journal of Psychopharmacology
72. Synthetic α-Conotoxin Mutants as Probes for Studying Nicotinic Acetylcholine Receptors and in the Development of Novel Drug Leads
    Christopher J. Armishaw · 2010 · Toxins
73. Development of Novel Pharmacotherapeutics for Tobacco Dependence: Progress and Future Directions
    Dympna Harmey, Patrick R. Griffin, Paul J. Kenny · 2012 · Nicotine & Tobacco Research
74. Current Insights into the Mechanisms and Development of Treatments for Heavy-Drinking Cigarette Smokers
    Daniel J. O. Roche, Lara A. Ray, Megan M. Yardley, Andrea C. King · 2016 · Current Addiction Reports
75. Varenicline ameliorates ethanol-induced deficits in learning in C57BL/6 mice
    Danielle Gulick, Thomas J. Gould · 2008 · Neurobiology of Learning and Memory
76. The Nicotinic Acetylcholine Receptor Partial Agonist Varenicline Increases the Ataxic and Sedative‐Hypnotic Effects of Acute Ethanol Administration in C57BL/6J Mice
    Helen M. Kamens, Jimena Andersen, Marina R. Picciotto · 2010 · Alcoholism Clinical and Experimental Research
77. Varenicline and neuronal nicotinic acetylcholine receptors: A new approach to the treatment of co‐occurring alcohol and nicotine addiction?
    Roberto Nocente, Mario Vitali, Giuseppe Balducci, Domenico Enea, Henry R. Kranzler, Mauro Ceccanti · 2013 · American Journal on Addictions
78. Autism - A Neurodevelopmental Journey from Genes to Behaviour
    Valsamma Eapen · 2011 · InTech eBooks
79. CC 4, a dimer of cytisine, is a selective partial agonist at α4β2/α6β2 nAChR with improved selectivity for tobacco smoking cessation
    Mariaelvina Sala, Daniela Braida, Luca Pucci, Irene Manfredi, Michael J. Marks, Charles R. Wageman, Sharon R. Grady, Barbara Loi, Sergio Fucile, Francesca Fasoli et al. · 2012 · British Journal of Pharmacology
80. Varenicline and cytisine: two nicotinic acetylcholine receptor ligands reduce ethanol intake in University of Chile bibulous rats
    Ramón Sotomayor‐Zárate, Katia Gysling, Usoa E. Busto, Bruce K. Cassels, Lutske Tampier, Marı́a Elena Quintanilla · 2013 · Psychopharmacology
81. Varenicline for smoking cessation: A review of the literature
    Kirandeep Kaur, Sandeep Kaushal, Sarvesh Chander Chopra · 2009 · Current Therapeutic Research
82. Neuropsychiatric Adverse Events of Varenicline: A Systematic Review of Published Reports
    Ahmed, Amir I.A., Ali, Abdullah N.A., Kramers, Cees, Härmark, Linda V.D., Burger, David M., Verhoeven, Willem M.A. · 2013 · Journal of Clinical Psychopharmacology
83. Ionotropic and metabotropic responses by alpha 7 nicotinic acetylcholine receptors
    Patricia Sinclair, Nadine Kabbani · 2023 · Pharmacological Research
84. The Effects of Galantamine on Psychopathology in Chronic Stable Schizophrenia
    Robert R. Conley, Douglas Lee Boggs, Deanna L. Kelly, Robert P. McMahon, Dwight Dickinson, Stephanie M. Feldman, M. Patricia Ball, Robert W. Buchanan · 2008 · Clinical Neuropharmacology
85. AT ‐1001: a high‐affinity α3β4 nAChR ligand with novel nicotine‐suppressive pharmacology
    Andrea Cippitelli, Jinhua Wu, Kelly A. Gaiolini, Daniela Mercatelli, Jennifer Schoch, Michelle Gorman, Alejandra Ramírez Muñoz, Roberto Ciccocioppo, Taline V. Khroyan, Dennis M. Yasuda et al. · 2014 · British Journal of Pharmacology
86. Locating Clinical Boundaries in the World Wide Web
    HENRY WHITE · 2009 · American Journal of Psychiatry
87. An Allosteric Modulator of α7 Nicotinic Receptors, N-(5-Chloro-2,4-dimethoxyphenyl)-N′-(5-methyl-3-isoxazolyl)-urea (PNU-120596), Causes Conformational Changes in the Extracellular Ligand Binding Domain Similar to Those Caused by Acetylcholine
    Sean C. Barron, J. T. McLaughlin, Jennifer A. See, Vanessa L. Richards, R. Rosenberg · 2009 · Molecular Pharmacology
88. Design, Synthesis, Structure–Activity Relationship Studies, and Three-Dimensional Quantitative Structure–Activity Relationship (3D-QSAR) Modeling of a Series of O-Biphenyl Carbamates as Dual Modulators of Dopamine D3 Receptor and Fatty Acid Amide Hydrolase
    Alessio De Simone, Debora Russo, G.F. Ruda, Alessandra Micoli, Mariarosaria Ferraro, Rita Maria Concetta Di Martino, Giuliana Ottonello, Maria Summa, Andrea Armirotti, Tiziano Bandiera et al. · 2017 · Journal of Medicinal Chemistry
89. Use of an α3β4 nicotinic acetylcholine receptor subunit concatamer to characterize ganglionic receptor subtypes with specific subunit composition reveals species-specific pharmacologic properties
    Clare A. Stokes, Roger L. Papke · 2012 · Neuropharmacology
90. The Role of Mesoaccumbens Dopamine in Nicotine Dependence
    David J.K. Balfour · 2015 · Current topics in behavioral neurosciences
91. Effect of the Nicotinic α4β2-receptor Partial Agonist Varenicline on Non-invasive Brain Stimulation-Induced Neuroplasticity in the Human Motor Cortex
    Giorgi Batsikadze, Walter Paulus, Jessica Grundey, Min‐Fang Kuo, Michael Andreas Nitsche · 2014 · Cerebral Cortex
92. Varenicline-Induced Mania in a Bipolar Patient
    Fadi J. Alhatem, James Black · 2009 · Clinical Neuropharmacology
93. Preclinical Evidence That Activation of Mesolimbic Alpha 6 Subunit Containing Nicotinic Acetylcholine Receptors Supports Nicotine Addiction Phenotype
    Darlene H. Brunzell · 2012 · Nicotine & Tobacco Research
94. Varenicline attenuates some of the subjective and physiological effects of intravenous nicotine in humans
    Mehmet Sofuoglu, Aryeh I. Herman, Marc E. Mooney, Andrew J. Waters · 2009 · Psychopharmacology
95. Medication Development for Alcohol Use Disorder: A Focus on Clinical Studies
    Lorenzo Leggio, Daniel E. Falk, Megan L. Ryan, Joanne B. Fertig, Raye Z. Litten · 2019 · Handbook of experimental pharmacology
96. Pharmacotherapy for Tobacco Dependence
    Reginald V. Fant, August R. Buchhalter, Albert C. Buchman, Jack E. Henningfield · 2009 · Handbook of experimental pharmacology
97. Nicotinic receptor partial agonists as novel compounds for the treatment of smoking cessation
    Piotr Tutka · 2008 · Expert Opinion on Investigational Drugs
98. Unique pharmacology of heteromeric α7β2 nicotinic acetylcholine receptors expressed in Xenopus laevis oocytes.
    R. Zwart, Merrick Strotton, J. Ching, P. Astles, E. Sher · 2014 · European Journal of Pharmacology
99. Varenicline Dose Dependently Enhances Responding for Nonpharmacological Reinforcers and Attenuates the Reinforcement-Enhancing Effects of Nicotine
    M. E. Levin, M. T. Weaver, Matthew Ian Palmatier, Anthony R. Caggiula, Alan F. Sved, Eric C. Donny · 2011 · Nicotine & Tobacco Research
100. The CHRNA5/A3/B4 Gene Cluster and Tobacco, Alcohol, Cannabis, Inhalants and Other Substance Use Initiation: Replication and New Findings Using Mixture Analyses
     Gitta H. Lubke, Sarah H. Stephens, Jeffrey M. Lessem, John K. Hewitt, Marissa A. Ehringer · 2012 · Behavior Genetics